BBC
Price
$38.15Alerts
Change
-$1.62 (-4.07%)
Updated
Nov 20, 04:59 PM (EDT)
Net Assets
32.69M
Intraday BUY SELL Signals
XBI
Price
$140.38Alerts
Change
-$3.74 (-2.60%)
Updated
Nov 20, 04:59 PM (EDT)
Net Assets
9.74B
Intraday BUY SELL Signals
Interact to see
Advertisement

BBC vs XBI

BBC vs XBI Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Nov 20, 2026

Which ETF would AI Choose? Virtus LifeSci Biotech Clinical Trials ETF (BBC) vs. State Street SPDR S&P Biotech ETF (XBI)

Key Takeaways

  • BBC is a niche, equal-weighted fund targeting early-stage, clinical-trial biotechnology companies, while XBI offers broader, equal-weighted exposure to the entire U.S. biotechnology industry.
  • XBI holds roughly 150–170 names spanning commercial-stage and clinical-stage biotechs, whereas BBC holds around 130 names concentrated in pre-approval drug developers with higher binary outcome risk.
  • Cost structure favors XBI, which carries a 0.35% expense ratio versus BBC's 0.65%, a meaningful gap for long-term holders.
  • XBI is far more liquid and institutionally established, with assets under management (AUM) in the billions, while BBC operates at a fraction of that scale.
  • Tickeron AI Verdict: XBI — the AI would favor XBI for its lower cost, deeper diversification, superior liquidity, and more consistent trend profile.

Introduction

Biotechnology ETFs have returned to the spotlight as renewed merger-and-acquisition (M&A) activity, a resilient innovation cycle, and shifting interest-rate expectations refocus investor attention on the sector. Comparing BBC and XBI is instructive because, although both target biotechnology equities, they occupy very different points on the risk spectrum. BBC isolates early-stage, clinical-trial companies whose fortunes hinge on binary trial outcomes, while XBI captures the full breadth of the U.S. biotech complex. Understanding this structural divergence is essential for investors weighing pure developmental-stage exposure against a more diversified, all-weather sector strategy.

Virtus LifeSci Biotech Clinical Trials ETF (BBC) Overview

BBC is a passively managed fund that seeks to track the LifeSci Biotechnology Clinical Trials Index. That index is equal-weighted and comprised of U.S.-listed biotechnology companies whose lead drug is typically in a Phase 1, Phase 2, or Phase 3 clinical trial, prior to receiving marketing approval. The fund launched in December 2014 and holds roughly 130 positions, with no single name dominating the portfolio — individual top holdings generally sit around 1% to 2% of assets.

Because it concentrates on pre-approval developers, BBC carries a distinctive risk profile: portfolio returns are heavily influenced by regulatory milestones, trial readouts, and financing events. The fund's sector allocation is essentially 100% healthcare, and it rebalances and reconstitutes its underlying index semi-annually. Its expense ratio is 0.65%, relatively high for a passive product, reflecting the specialized index it tracks. With comparatively modest AUM and trading volume, BBC is best suited to investors with a high risk tolerance and a conviction view on early-stage drug development.

State Street SPDR S&P Biotech ETF (XBI) Overview

XBI is a passively managed fund that tracks the S&P Biotechnology Select Industry Index, a modified equal-weighted benchmark representing the biotechnology segment of the S&P Total Market Index. Launched in January 2006, XBI is one of the most established and heavily traded biotech ETFs, with AUM measured in the billions and a portfolio of roughly 155–170 holdings.

XBI's equal-weighted construction prevents the largest names from dominating returns, giving meaningful exposure to small- and mid-cap innovators alongside established players. Top holdings have historically included companies such as MRNA, NTRA, HALO, BIIB, and AMGN, each typically weighted around 1.5% to 2.5% of assets. Its expense ratio is 0.35%, among the lowest in the category, and its near-100% biotechnology allocation spans both clinical-stage and commercially profitable companies, offering a more balanced risk/reward profile than BBC.

Industry and Thematic Backdrop

Both funds operate within a biotechnology sector shaped by several overlapping forces. A notable pickup in pharmaceutical M&A (mergers and acquisitions) has rekindled investor appetite, as cash-rich large-cap drugmakers acquire promising assets to replenish pipelines. Regulatory dynamics at the U.S. Food and Drug Administration (FDA), drug-pricing policy debates, and the trajectory of interest rates also weigh on sentiment, because early-stage biotechs are disproportionately sensitive to the cost of capital.

Advancements in areas such as genetic medicine, oncology, and obesity and metabolic treatments continue to drive innovation and attract capital. At the same time, sector risks remain elevated: clinical failures can erase value overnight, and financing conditions can tighten quickly. This backdrop favors diversified, liquid vehicles over concentrated early-stage exposure when risk appetite is mixed.

Performance and Positioning Comparison

In recent weeks and across recent market cycles, XBI has demonstrated a more consistent and institutional-quality trend profile than BBC. XBI's broader mix of commercial-stage and late-stage companies tends to smooth out the sharp, binary swings that characterize BBC's clinical-stage holdings. When sector rotation favors biotech broadly, both funds benefit, but XBI's diversification and deeper liquidity typically translate into steadier relative positioning and narrower volatility dispersion across its constituents.

BBC, by contrast, is a higher-beta expression of the same theme. Its performance is more tightly coupled to trial outcomes and financing windows among early-stage developers, which can produce outsized moves in both directions. Cost also compounds this divergence over time: BBC's 0.65% expense ratio versus XBI's 0.35% represents a persistent drag that favors XBI for buy-and-hold investors. On a risk-adjusted basis, XBI's superior liquidity, lower cost, and broader diversification make it the more resilient vehicle through uneven market conditions.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to surface ideas aligned with your own strategy and risk profile.

Tickeron AI Verdict

Based on observable structural factors, Tickeron's AI would currently favor XBI over BBC. XBI combines a materially lower expense ratio, substantially greater liquidity and scale, broader diversification across both clinical- and commercial-stage companies, and a more consistent trend profile. While BBC offers a purer, higher-octane bet on early-stage drug development, that focus also amplifies concentration risk and binary-outcome volatility. In probabilistic terms, XBI's balance of cost efficiency, diversification, and relative positioning presents a more defensible core allocation within the biotechnology theme, whereas BBC is better characterized as a tactical, high-conviction satellite position for risk-tolerant investors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
BBC vs. XBI commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBC is a Hold and XBI is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BBC with price predictions
Nov 20, 2026

BBC sees MACD Histogram just turned negative

BBC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 17, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 45 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBC as a result. In 62 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The 50-day moving average for BBC moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BBC's RSI Indicator exited the oversold zone, 27 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +10.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBC advanced for three days, in 275 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 201 of 220 cases where BBC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

A.I.Advisor
a Summary for XBI with price predictions
Nov 20, 2026

XBI's Stochastic Oscillator is remaining in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 82 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 48 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

TECHNICAL ANALYSIS
Technical Analysis
BBCXBI
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
90%
Bullish Trend 12 days ago
90%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement

XBI and

Correlation & Price change

A.I.dvisor indicates that over the last year, XBI has been loosely correlated with RCUS. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XBI jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBI
1D Price
Change %
XBI100%
-2.73%
RCUS - XBI
60%
Loosely correlated
-1.01%
VYGR - XBI
59%
Loosely correlated
-4.97%
LYEL - XBI
57%
Loosely correlated
+1.62%
LGND - XBI
56%
Loosely correlated
-0.03%
MGNX - XBI
55%
Loosely correlated
-1.01%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SMDX25.50N/A
N/A
Intech S&P Small-Mid Cap Diversified Alpha ETF
AMUB20.41-0.39
-1.85%
ETRACS Alerian MLP Index ETN Class B (AMUB)
KYN12.97-0.25
-1.89%
Kayne Anderson Energy Infrastructure Fund
WDNA20.58-0.66
-3.12%
WisdomTree BioRevolution Fund (WDNA)
SPYU20.82-3.44
-14.18%
MAX S&P 500 4X Leveraged ETN (SPYU)